AtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Algert Global LLC

Algert Global LLC grew its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 10.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,199 shares of the medical device company's stock after purchasing an additional 8,787 shares during the period. Algert Global LLC owned approximately 0.20% of AtriCure worth $2,940,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in AtriCure by 1.8% during the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after purchasing an additional 265 shares in the last quarter. Invesco Ltd. grew its stake in shares of AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after acquiring an additional 334 shares in the last quarter. Perkins Capital Management Inc. increased its position in shares of AtriCure by 1.3% during the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock worth $927,000 after acquiring an additional 400 shares during the last quarter. Truist Financial Corp lifted its stake in shares of AtriCure by 2.6% in the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after acquiring an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of AtriCure by 0.9% in the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after acquiring an additional 484 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.50% of the company's stock.

AtriCure Stock Performance

ATRC stock traded down $0.14 during trading on Tuesday, hitting $31.67. 101,051 shares of the company's stock traded hands, compared to its average volume of 654,013. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -33.34 and a beta of 1.57. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The stock has a fifty day moving average price of $32.59 and a two-hundred day moving average price of $34.85. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. The business had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The company's revenue for the quarter was up 13.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ATRC shares. BTIG Research restated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. JMP Securities reissued a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a research report on Wednesday, April 30th. JPMorgan Chase & Co. cut their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. Oppenheimer increased their price objective on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group dropped their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.